GlassScriptPhysician profile
Dilawar Khan
NPI 1588725188
$56,892.16
in general payments reported to CMS, 2019-2025
42 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $6,413 · 2021: $4,349 · 2022: $13K · 2023: $19K · 2024: $12K · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $3,357 · Honoraria: $2,600 · Food and Beverage: $2,039 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,303.50 |
| Travel and Lodging | $3,356.88 |
| Honoraria | $2,600.00 |
| Food and Beverage | $2,038.53 |
| Education | $118.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $11,466.25 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Astrazeneca Pharmaceuticals LP | $7,948.95 | 2020-2024 | Imfinzi, Lynparza |
| Genentech USA, INC. | $6,946.18 | 2022-2023 | Lunsumio, Polivy, Columvi |
| Eisai INC. | $4,879.69 | 2020-2024 | |
| Deciphera Pharmaceuticals INC. | $4,790.60 | 2022 | |
| Glaxosmithkline, LLC. | $4,235.81 | 2020-2024 | Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $2,982.19 | 2019-2024 | |
| Novocure INC. | $2,600.00 | 2024 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $2,476.20 | 2023-2024 | |
| Pfizer INC. | $1,331.22 | 2020-2024 | |
| Kite Pharma, INC. | $1,300.00 | 2020 | |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,221.00 | 2024 | |
| Daiichi Sankyo INC. | $674.99 | 2021-2022 | |
| Beigene USA, INC. | $525.00 | 2022 |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilawar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.